Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2016017227
pages 127-139

The Transcription Regulator Kruppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma

Swapan K. Ray
Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Building 2, Room C11, 6439 Garners Ferry Road, Columbia, SC 29209


The Kruppel-like factor 4 (KLF4) gene is located on chromosome 9q31. All of the currently known 17 KLF transcription regulators that have similarity with members of the specificity protein family are distinctly characterized by the Cys2/His2 zinc finger motifs at their carboxyl terminals for preferential binding to the GC/GT box or the CACCC element of the gene promoter and enhancer regions. KLF4 is a transcriptional regulator of cell proliferation, differentiation, apoptosis, migration, and invasion, emphasizing its importance in diagnosis and prognosis of particular tumors. KLF4 has been implicated in tumor progression as well as in tumor suppression, depending on tumor types and contexts. Different studies so far strongly suggest that KLF4 acts as an oncogene in glioblastoma, which is the most malignant and prevalent brain tumor in human adult. It is now well established that the presence of glioblastoma stem cells (GSCs) in glioblastoma causes therapy resistance and progressive growth of the tumor. Because KLF4 is one of the key stemness factors in GSCs, it is likely that KLF4 contributes significantly to the survival of GSCs and the recurrence of glioblastoma. On the other hand, recent studies show that KLF4 can act as a tumor suppressor in human malignant neuroblastoma, which is a deadly tumor mostly in children, by inhibiting the cell cycle and activating the cell differentiation and death pathways. Our increasing understanding of the molecular mechanisms of the contrasting roles of KLF4 in glioblastoma and neuroblastoma is useful for superior diagnosis, therapy, and prognosis of these tumors of the nervous system.

Articles with similar content:

PTHrP Gene Expression in Cancer: Do All Paths Lead to Ets?
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 2
John Foley, Thomas J. Rosol, Virgile Richard
KLF4 in Ovarian Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Lawrence M. Pfeffer, Baojin Wang, Ziyun Du, Junming Yue
Tissue-Specific Transformation by Oncogenic Mutants of Epidermal Growth Factor Receptor
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 4
H. J. Kung, T. H. Carter
Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Mignon L. Loh, Sarah Tasian
Genetic and Epigenetic Control of RKIP Transcription
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Milad S. Bitar, Kevin Qin, Kam C. Yeung, Fahd Al-Mulla, Hanna Tegegne, Ila Datar, Robert J. Trumbly